TruGraf Liver Gene Expression Serial Test
Conditions: Autoimmune Liver Disease; Autoimmune Hepatitis; Primary Sclerosing Cholangitis; Primary Biliary Cirrhosis Interventions: Diagnostic Test: TruGraf ® Sponsors: Washington University School of Medicine; Transplant Genomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
Conditions: Metabolic Dysfunction-associated Fatty Liver Disease Sponsors: The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang Chinese Medical University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Conditions: Liver Diseases; Hepatocellular Carcinoma; Immunotherapy; Camrelizumab; Lenvatinib Interventions: Procedure: bTAE-HAIC; Drug: Lenvatinib; Drug: Camrelizumab Sponsors: Zhou Qunfang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Multi-morbidity Screening in People With Type 2 Diabetes and Pre Diabetes
Conditions: Type 2 Diabetes; Pre Diabetes; Obstructive Sleep Apnea; Non-Alcoholic Fatty Liver Disease; Heart Failure Sponsors: University of Liverpool Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Condition: Liver Cirrhosis Interventions: Diagnostic Test: EUS guided liver biopsy; Diagnostic Test: Percutaneous Liver Biopsy Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Condition: Liver Cirrhosis Interventions: Diagnostic Test: EUS guided liver biopsy; Diagnostic Test: Percutaneous Liver Biopsy Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Condition: Liver Cirrhosis Interventions: Diagnostic Test: EUS guided liver biopsy; Diagnostic Test: Percutaneous Liver Biopsy Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Condition: Liver Cirrhosis Interventions: Diagnostic Test: EUS guided liver biopsy; Diagnostic Test: Percutaneous Liver Biopsy Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
